Silo Pharma Explores Ibogaine for TBI & Neuropsychiatric Conditions

Silo Pharma Explores Ibogaine for TBI & Neuropsychiatric Conditions

Silo Pharma Inc. is researching ibogaine-based treatments for traumatic brain injury and related conditions, aiming to address underserved health issues.

Federal Support Boosts Psychedelic Therapeutics

Silo Pharma Inc. highlights U.S. federal momentum backing the development of psychedelic-based therapies for mental health and substance use disorders, anticipating innovation in treating conditions such as PTSD and addiction.

Federal Support Boosts Psychedelic Therapeutics

Silo Pharma Inc. highlights U.S. federal actions advancing the development of psychedelic-based therapies for mental health and substance use disorders, anticipating innovation in PTSD and addiction treatment.

Optimi Health Corp. Ibogaine Initiative

Optimi Health Corp. launches an Ibogaine Initiative to meet demand for pharmaceutical-grade ibogaine and expand its global strategy in psychedelic therapies, aligning with U.S. regulatory changes.

Psychedelic Therapy Companies Embrace White House Executive Order

Helus Pharma(TM) and NRx Pharmaceuticals show support for the Executive Order promoting psychedelic therapies, emphasizing research acceleration and patient access.